EFFECT OF HALVING THE DOSE OF THE BETA -BLOCKER DURING TREATMENT OF HYPERTENSION WITH OXPRENOLOL COMBINED WITH HYDRALAZINE. A MULTICENTRE STUDYFRITHZ G; WERNERSSON B.1980; CURR. THERAPEUT. RES.; USA; DA. 1980; VOL. 27; NO 1; PP. 22-28; BIBL. 4 REF.Article

SINGLE VERSUS MULTIPLE DAILY ADMINISTRATION OF HYDRALAZINE IN THE MAINTENANCE TREATMENT OF HYPERTENSIONHENNINGSEN NC; HANSON A; WERNERSSON B et al.1982; ACTA MED. SCAND.; ISSN 0001-6101; SWE; DA. 1982; VOL. 211; NO 3; PP. 179-185; BIBL. 26 REF.Article

HYDRALAZINE ONCE DAILY IN THE MAINTENANCE TREATMENT OF HYPERTENSIONDANIELSON M; KJELLBERG J; WERNERSSON B et al.1981; CURR. THER. RES.; ISSN 0011-393X; USA; DA. 1981; VOL. 29; NO 1; PART. 1; PP. 102-111; BIBL. 23 REF.Article

Evaluation of once daily hydralazine in inadequately controlled hypertensionDANIELSON, M; KJELLBERG, J; OHMAN, P et al.Acta medica Scandinavica. 1983, Vol 214, Num 5, pp 373-380, issn 0001-6101Article

Impact of persistent, frequent regurgitation on quality of life in heartburn responders treated with acid suppression: a multinational primary care studyKAHRILAS, P. J; HOWDEN, C. W; WERNERSSON, B et al.Alimentary pharmacology & therapeutics. 2013, Vol 37, Num 10, pp 1005-1010, issn 0269-2813, 6 p.Article

Dyspepsia and irritable bowel syndrome in China: a population-based endoscopy study of prevalence and impactZHAO, Y; ZOU, D; YIN, P et al.Alimentary pharmacology & therapeutics. 2010, Vol 32, Num 4, pp 562-572, issn 0269-2813, 11 p.Article

Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary careJONES, R; JUNGHARD, O; DENT, J et al.Alimentary pharmacology & therapeutics. 2009, Vol 30, Num 10, pp 1030-1038, issn 0269-2813, 9 p.Article

Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis ― a post hoc analysis of 5796 patientsBYTZER, P; ZANTEN, S. Veldhuyzen Van; MATTSSON, H et al.Alimentary pharmacology & therapeutics. 2012, Vol 36, Num 7, pp 635-643, issn 0269-2813, 9 p.Article

Clinical efficacy of hydralazine in chronic heart failure: one-year double-blind placebo-controlled studyCONRADSON, T.-B; RYDEN, L; AHLMARK, G et al.The American heart journal. 1984, Vol 108, Num 4, pp 1001-1006, issn 0002-8703Article

Predictors of either rapid healing or refractory reflux oesophagitis during treatment with potent acid suppressionKAHRILAS, P. J; PERSSON, T; DENISON, H et al.Alimentary pharmacology & therapeutics. 2014, Vol 40, Num 6, pp 648-656, issn 0269-2813, 9 p.Article

Validation of the GerdQ questionnaire for the diagnosis of gastro-oesophageal reflux diseaseJONASSON, C; WERNERSSON, B; HOFF, D. A. L et al.Alimentary pharmacology & therapeutics. 2013, Vol 37, Num 5, pp 564-572, issn 0269-2813, 9 p.Article

Pharmacokinetics of oral hydralazine in chronic heart failureHANSON, A; JOHANSSON, B. W; WERNERSSON, B et al.European journal of clinical pharmacology. 1983, Vol 25, Num 4, pp 467-473, issn 0031-6970Article

MAINTENANCE TREATMENT OF HYPERTENSION WITH BETA-BLOCKERS AND DIURETICS IN FIXED-RATIO COMBINATIONBERGSTROEM M; CERNE P; EHINGER C et al.1980; CURR. THERAPEUT. RES.; USA; DA. 1980; VOL. 27; NO 6; PART. 1; PP. 805-811; BIBL. 2 P.Article